Pages
Products
GFP Adeno-Associated Virus ( AAV-MTP )

GFP Adeno-Associated Virus ( AAV-MTP )

Cat.No. :  AAV00433Z

Titer: ≥1x10^12 GC/mL / ≥1x10^13 GC/mL Size: 30 ul/100 ul/500 ul/1 ml

Serotype:  AAV Serotype 2 Storage:  -80 ℃

Inquire for Price

AAV Particle Information

Quality Control

Cat. No. AAV00433Z
Description This virus is a reporter AAV with capsid engineering / modification. GFP AAV-MTP particles contain engineered capsid derived from AAV serotype 2 (AAV2) which has insertion of peptides MTPFPTSNEANL at I587. The target cell type of this capsid engineered AAV is endothelial cells.
Reporter GFP
Serotype AAV Serotype 2
Target Gene GFP
Application

1. Determination of optimal MOI (multiplicity of infection), administration methods etc.

2. Detection of the infection efficiency of the AAV serotype against a specific cell type or tissue.

3. Using reporter genes to visualize the distribution and expression of AAV vectors in live animals, helping assess the biodistribution and persistence of gene delivery.

Titer Varies lot by lot, typically ≥1x10^12 GC/mL
Size Varies lot by lot, for example, 30 μL, 50 μL, 100 μL etc.
Storage Store at -80℃. Avoid multiple freeze/thaw cycles.
Shipping Frozen on dry ice
Creative Biogene ensures high-quality AAV particles by optimizing and standardizing production protocols and performing stringent quality control (QC). The specific QC experiments performed vary between AAV particle lots.
Endotoxin Endotoxins, primarily derived from Gram-negative bacteria, can trigger adverse immune responses. Endotoxin contamination is a significant concern in the production of AAV, especially for applications in animal studies and gene therapy. Effective endotoxin quality control is essential in the development and manufacturing of AAV particles. Creative Biogene utilizes rigorous endotoxin detection methods to monitor the endotoxin level in our produced AAV particles to ensure regulatory compliance.
Purity AAV purity is critical for ensuring the safety and efficacy of AAV-based applications.AAV capsids are composed of three main protein components, known as viral proteins: VP1, VP2, and VP3. These proteins play a critical role in the structure and functionality of the AAV capsid. Monitoring the VP1, VP2, and VP3 content in AAV preparations is essential for quality control in AAV production. Our AAV particles are tested for showing three clear bands of VP1, VP2 VP3 by SDS-PAGE.
Sterility The AAV virus samples are inoculated into the cell culture medium for about 5 days to detect bacterial and fungal growth.
Transducibility Upon requirement, Creative Biogene can perform in vitro or in vivo transduction assays to evaluate the ability of AAV to deliver genetic material into target cells or tissues, and assess gene expression and functional activities.
Empty vs. Full Capsids Based-on our proprietary AAV production and purification technology, Creative Biogene can always offer AAV particles with high ratio of full capsids. If required, we can also assess the ratio for a specifc lot of AAV particles by transmission electron microscopy (TEM) or other methods.
Quick Inquiry

Background

Publications

Q & A

Customer Reviews

Endothelial cells (ECs) have been used to treat pathological conditions such as atherosclerosis, hypercholesterolemia, restenosis after angioplasty, and hypertension. Nonpathogenic adeno-associated virus (AAV) has been shown to be a good tool for gene delivery in a variety of cell lines as well as in animal models. However, AAV-induced transduction of endothelial cells has been reported to be low. Transduction of HUVECs by AAV vectors alone was much lower than that of other cell lines, including Hela, PAC1, and C2C12. Preincubation of AAV vectors with EC membrane-specific peptides significantly increased AAV transduction of HUVECs. In contrast, these peptides did not affect AAV expression in other cell types. These EC-specific peptides may be a strategy to enhance AAV-mediated gene expression. AAV-MTP particles are derived from AAV serotype 2 (AAV2), a well-characterized and extensively studied serotype known for its efficient transduction of various cell types. Engineering of the AAV2 capsid involves the incorporation of a specific peptide sequence, MTPFPTSNEANL, at position I587. This modification significantly enhances the virus's ability to selectively target and transduce endothelial cells, the cells that line the inner surface of blood vessels.
Customer Q&As
Can AAV cause an immune response?

A: AAV causes a very mild immune response, lending further support to its apparent lack of pathogenicity.

How much transgene can AAV hold?

A: One of the limitations of AAV is its transfer capacity of about 5 kb, which can be extended to about 9 kb using dual AAV carriers.

Ask a Question

If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.

Customer Reviews
Robust GFP Expression

We’ve been using the GFP AAV-MTP for several months now, and the GFP expression has been outstanding. The stability and brightness of GFP in endothelial cells allow for clear visualization and analysis.

United Kingdom

08/27/2021

Enhanced Research Capabilities

With the specifically engineered AAV2 capsid containing the MTPFPTSNEANL peptide, the GFP AAV-MTP has expanded our research capabilities. We’ve been able to explore endothelial cell functions and behaviors with unprecedented clarity and precision.

French

06/10/2020

Write a Review

Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.

Needs improvement

Satisfaction

General satisfaction

Very satisfaction